Clinical trial · Observational
Vandetanib Risk Minimisation Effectiveness
Effectiveness of Risk Minimisation Interventions for Vandetanib in Canada
NCT01757470CI-TRIAL-00023736completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Effectiveness of risk minimisation interventions for vandetanib in Canada
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Medullary Thyroid Cancer | Thyroid Gland Medullary Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- Caprelsa Patient
- description
- All patients treated with Caprelsa in Canada and participating in the restricted distribution programme.
- label
- Caprelsa Prescriber
- description
- All physicians having prescribed at least one dose of Caprelsa and registered as a certified prescriber of Caprelsa in Canada.
Primary outcomes (13)
- measure
- Knowledge and Understanding Survey: Knowledge of the key safety issues pertaining to vandetanib
- timeFrame
- 2 months
- description
- QT prolongation/TdP Torsades, diarrhea, rash and other skin reactions- adequate or inadequate for each safety issue (defined by correct response).
- measure
- Drug Utilisation Study: Use of vandetanib - duration of treatment at baseline
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: \- N/A (all patients taking Caprelsa and all prescribers will be contacted for participation). Exclusion Criteria: - N/A
References
Publications (0)
Data not yet available
No reference posted for this study.